HIV/AIDS

HIV patients are more likely to be depressed, which reduces treatment adherence. Here’s how dogs could help.

A study of over 20 years of cancer incidences show the therapy may have broken the trend.

A study found that the demographic characteristics of patients who failed to initiate ART within 2 years of entering care were not as important as clinical factors.

The rates of viral rebound in people with long-term viral suppression on first-line regimens have become "extremely low," according to a study.

Surveyed LGB adults also reported notably greater rates of heart conditions with more lesbian and bisexual women reporting strokes and heart attacks than heterosexual women, and more gay and bisexual men reporting chest pain related to heart disease than heterosexual men.

The UNC-based research covered the period from January 2003 to December 2012, when most patients in the study were not covered by the most recent federal guidelines pertaining to HIV treatment.

Neurotoxin EB-001's fast treatment start-up and shorter duration could make for a different focal pain reliever.

Cesarean sections can lead to higher rates of respiratory distress syndrome and transient tachyprea.

It’s more effective and cheaper than present technology, researchers said.

The powder form will be more easily administered to pediatric patients, AbbVie says.

Isentress HD (raltegravir) is a new dosage of previously approved treatment.

Combination ART treatment has substantially improved the life expectancy of HIV patients; 10 years in men and 9 in women.

Prisons are breeding grounds for STIs, including HIV. What can fix that?

Researchers analyzed liver fibrosis levels in HIV, hepatitis B coinfection.

A panel wants the FDA to restrict an opioid because abusers are injecting it.

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), shared with MD Magazine what the main theme would be in his keynote address at the AAAAI 2017 meeting in Atlanta, GA: emerging and reemerging infections, a perpetual challenge.

Katia Boven, MD, Head of Clinical Development and Global Medical Affairs, Infectious Diseases, Janssen, discussed results and impact of the SWORD clinical trial involving the investigational two-drug combination being as effective as the three or four regimens as maintenance therapy in HIV patients who have already achieved viral suppression.